Skip to main content
. 2021 Jan 15;39(7):723–733. doi: 10.1200/JCO.20.01605

FIG A4.

FIG A4.

PFS in patients with (A) SQ tumor histology, (B) NSQ tumor histology, (C) ≥ 1% PD-L1 expression, and (D) < 1% PD-L1 expression. aPer local investigator; minimum follow-up: CheckMate 017: 64.2 months and CheckMate 057: 64.5 months. HR, hazard ratio; NC, not calculable; No., number; NSQ, nonsquamous; PD-L1, programmed death ligand 1; PFS, progression-free survival; SQ, squamous.